Abstract: Provided herein are nano-emulsion compositions comprising a cannabinoid, a solvent, a lipid source, and a surfactant. Methods of making the nano-emulsion compositions and methods of use are also provided herein. Compositions comprising the nano-emulsion compositions, such as food and beverage compositions and topical compositions, are also provided herein.

Abstract: The present disclosure describes a method which outlines a process for conversion of CBD to a ?9-tetrahydrocannabinol (?9-THC) compound or derivative thereof involving treating a naturally produced CBD intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the ?9-tetrahydrocannabinol compound or derivative thereof at a relatively high concentration. The source of the CBD is from industrial hemp having less than 0.3% ?9-THC and extracting and purifying a CBD distillate or isolate or a combination thereof. This procedure will produce ?9-THC that is essentially free from any other cannabinoids other than some trace amounts of the initial CBD starting material, or about 95% ?9-THC and 2-4% CBD. Another aspect of the present invention relates to a process for further purification and enrichment of the ?9-THC using distillation and collecting an essentially pure fraction of ?9-THC using additional distillation or enrichment form of purification.

Abstract: The present invention describes a method which outlines a process for conversion of CBD to a ?9-tetrahydrocannabinol (?9-THC) compound or derivative thereof involving treating a naturally produced CBD intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the ?9-tetrahydrocannabinol compound or derivative thereof at a relatively high concentration. The source of the CBD is from industrial hemp having less than 0.3% ?9-THC and extracting and purifying a CBD distillate or isolate or a combination thereof. This procedure will produce ?9-THC that is essentially free from any other cannabinoids other than some trace amounts of the initial CBD starting material, or about 95% ?9-THC and 2-4% CBD. Another aspect of the present invention relates to a process for further purification and enrichment of the ?9-THC using distillation and collecting an essentially pure fraction of ?9-THC using additional distillation or enrichment form of purification.

Abstract: The invention relates to a novel process for making lisdexamfetamine dimesylate and related derivatives by the novel amino acid activation and amphetamine acylation in the presence of water or alcohols. A second invention relates to the novel process for making lisdexamfetamine dimesylate from racemic amphetamine compounds where the single isomer product is isolated without a chemical or enzymatic resolution.

Abstract: The present invention describes a method which outlines a process for conversion of CBD to a ?9-tetrahydrocannabinol (?9-THC) compound or derivative thereof involving treating a naturally produced CBD intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the ?9-tetrahydrocannabinol compound or derivative thereof at a relatively high concentration. The source of the CBD is from industrial hemp having less than 0.3% ?9-THC and extracting and purifying a CBD distillate or isolate or a combination thereof. This procedure will produce ?9-THC that is essentially free from any other cannabinoids other than some trace amounts of the initial CBD starting material, or about 95% ?9-THC and 2-4% CBD. Another aspect of the present invention relates to a process for further purification and enrichment of the ?9-THC using distillation and collecting an essentially pure fraction of ?9-THC using additional distillation or enrichment form of purification.

Abstract: The present invention describes a method which outlines a process for conversion of CBD to a ?9-tetrahydrocannabinol (?9-THC) compound or derivative thereof involving treating a naturally produced CBD intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the ?9-tetrahydrocannabinol compound or derivative thereof at a relatively high concentration. The source of the CBD is from industrial hemp having less than 0.3% ?9-THC and extracting and purifying a CBD distillate or isolate or a combination thereof. This procedure will produce ?9-THC that is essentially free from any other cannabinoids other than some trace amounts of the initial CBD starting material, or about 95% ?9-THC and 2-4% CBD. Another aspect of the present invention relates to a process for further purification and enrichment of the ?9-THC using distillation and collecting an essentially pure fraction of ?9-THC using additional distillation or enrichment form of purification.

Abstract: This is invention is related to processes for synthesis of levoamphetamine derivatives and novel intermediates thereby, and processes for using the same.

Abstract: The present invention describes chemical processes for making optically-clear, taste-masked, shelf-stable nano-emulsions containing essentially pure cannabinoids and other nutraceuticals.

Abstract: The present invention describes a method which outlines a process for conversion of CBD to a ?9-tetrahydrocannabinol (?9-THC) compound or derivative thereof involving treating a naturally produced CBD intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the ?9-tetrahydrocannabinol compound or derivative thereof at a relatively high concentration. The source of the CBD is from industrial hemp having less than 0.3% ?9-THC and extracting and purifying a CBD distillate or isolate or a combination thereof. This procedure will produce ?9-THC that is essentially free from any other cannabinoids other than some trace amounts of the initial CBD starting material, or about 95% ?9-THC and 2-4% CBD. Another aspect of the present invention relates to a process for further purification and enrichment of the ?9-THC using distillation and collecting an essentially pure fraction of ?9-THC using additional distillation or enrichment form of purification.

Abstract: This is invention is related to processes for synthesis of levoamphetamine derivatives and novel intermediates thereby, and processes for using the same.

Abstract: A compound having formula (I), wherein A is selected from the group consisting of: (i) phenyl, wherein said phenyl is optionally substituted by one or more halogen atoms, C1-6alkyl, C1-3alkoxy, C1-3fluoroalkoxy, nitrile, or —NR7R8 where R7 and R8 are independently hydrogen or C1-3alkyl; (ii) a 5- or 6-membered hetrocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfur; and (iii) a fused bicyclic ring (a), wherein ring C represents a heterocyclic group as defined in point (ii) above, which bicyclic ring is attached to group B via a ring atom of ring C; B is selected from the group consisting of: (iv) C1-6alkylene; (v) —MC1-6alkylene or C1-6alkyleneMC1-6alkylene, wherein M is O, S, or —NR2 wherein R2 represents hydrogen or C1-3alkyl; (vi) a 5- or 6-membered heterocyclic group containing at least one nitrogen heteroatom and optionally at least one further heteroatom selected from oxygen, nitrogen and sulfur and optionally substituted by C1-3alkyl; and (vii) H

Abstract: Benzo?b!?1,4!diazepine compounds of formula (I), where R.sup.1 is selected from C.sub.1 C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, phenyl, or substituted phenyl; R.sup.2 is selected from C.sub.3 -C.sub.6 alkyl, C.sub.3 C.sub.6 cycloalkyl, C.sub.3 -C.sub.6 alkenyl, benzyl, phenylC.sub.1 -C.sub.3 alkyl of substituted phenyl; or NR.sup.1 R.sup.2 together form 1,2,3,4-tetrahydroquinoline or benzazepine, mono-, di-, or trisubstituted independently with C.sub.1-6 alkyl C.sub.1-6 alkoxy or halogen substituents; p is an integer 0 or 1; q is an integer 0 or 1; r is an integer 0 or 1; t is an integer 0 or 1, provided that when r is 0 then t is 0; R.sup.3, R.sup.5, and R.sup.6 are independently hydrogen or C.sub.1-6 alkyl; R.sup.4 is C.sub.1-6 alkyl or C.sub.1-6 alkenyl; R.sup.7 is selected from the group consisting of hydrogen, C.sub.1-6 alkyl, C.sub.1-6 cycloalkyl, C.sub.1-6 alkenyl, phenyl, substituted phenyl, napthyl, heteroaryl, substituted heteroaryl, bicycloheteroaryl or substituted bicycloheteroaryl; or NR.sup.

Abstract: A novel three-step process for resolving a racemic spiro-hydantoin compound into its optical antipodes is disclosed, which involves (1) reacting said racemic compound with an optically-active asymmetric isocyanate of the formula RNCO, wherein R is (S)- or (R)-1-phenylethyl or (S)-or (R)-1-(1-naphthyl)ethyl, to form the corresponding diastereomeric ureido compound; (2) separating the resulting diastereomeric mixture into its component parts, and (3) thereafter converting the separated ureido diasteromers obtained in step (b) to the corresponding asymmetric hydantoin compounds by treatment with an alkali metal lower alkoxide (C.sub.1 -C.sub.4), followed by acidification, whereupon the desired optical isomer is obtained.

Abstract: A novel three-step process for resolving a racemic spiro-hydantoin compound into its optical antipodes is disclosed, which involves (1) reacting said racemic compound with an optically-active asymmetric isocyanate of the formula RNCO, wherein R is (S)- or (R)-1-phenylethyl or (S) or (R)-1-(1-naphthyl)ethyl, to form the corresponding diastereomeric uredio compound; (2) separating the resulting diastereomeric mixture into its component parts, and (3) thereafter converting the separated ureido diastereomers obtained in step (b) to the corresponding asymmetric hydantoin compounds by treatment with an alkali metal lower alkoxide (C.sub.1 -C.sub.4), followed by acidification, whereupon the desired optical isomer is obtained.